Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
Advances in molecular genetics have aided the identification of potential biomarkers with significant clinical promise in neurooncology. These advances and the evolution of targeted therapeutics necessitate the development and incorporation of innovative clinical trial designs that can effectively validate and assess the clinical utility of biomarkers. In this article, we review the use and potential of several such designs in neurooncology trials in order to support the development of personalized treatment approaches for brain tumor patients.
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. galanis.evanthia@mayo.edu
Evanthia
E
Galanis
Wenting
W
Wu
Jann
J
Sarkaria
Susan M
SM
Chang
Howard
H
Colman
Daniel
D
Sargent
David A
DA
Reardon
D024221:Antineoplastic Protocols; D014408:Biomarkers, Tumor / Q000032:analysis*; D001932:Brain Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D008967:Molecular Biology / Q000379:methods*; D057285:Precision Medicine / Q000379:methods*; D012107:Research Design
D014408:Biomarkers, Tumor